Tomorrow’s Treatments. Today.
Around the world, groundbreaking clinical trials offer new hope. And it’s happening now in Central California.
We’re working in partnership with UCSF to bring international clinical cancer trials to patients in the Central Valley – providing access to new treatments before they’re available to the public.
As a member of three large cooperative groups sponsored by the National Cancer Institute (NCI), we have access to treatments that give some patients more options without having to travel far from home or change doctors.
We offer clinical trials for cancers in breast, cervical/endometrial, lung, pancreatic, prostate, renal cell, colon, rectal, HCC and anaplastic glioma tumors. And our partners at the UCSF clinical research program are pursuing research opportunities in Hodgkin’s Lymphoma and NHL, multiple myeloma, AML, metastatic NSCLC, and brain tumors.
One of the final stages of the cancer research process, clinical trials seek to determine whether promising approaches to cancer prevention, diagnosis and treatment are safe and effective. And in so doing, researchers and patients alike are contributing to the body of knowledge in the fight against cancer.
If you‘re considering a clinical trial, we’ll explain the purpose of the trial, the expected benefits, anticipated side effects or risks as well as what will be expected of you. Even if you sign a consent form, you can leave a clinical trial at any time without penalty.
Oncology Clinical Trials Currently Available for Enrollment
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-Cell ALL
Bristol Myers Squibb
A Phase 3 Randomized, Double Blind, Multi-center Study of Adjuvant Nivolumab versus Placeb in Subjects with High Rish Invasive Urothelial Carcinoma
A randomized phase III trial comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer patients (CT1-3 N1) who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone ReceptorPositive Advanced Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Alternate approaches for clinical stage II or III estrogen receptor positive breast cancer neoadjuvant treatment (ALTERNATE) in postmenopausal women: A phase III study
A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive HER2 negative breast cancer: The ABC trial
A Phase II/III, Randomized, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND
Bristol Myers Squibb
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair
A PHASE III RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF ARMODAFINIL (NUVIGIL®) TO REDUCE CANCER-RELATED FATIGUE IN PATIENTS WITH HIGH GRADE GLIOMA
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Molecular Analysis for Therapy Choice (MATCH)
CA209-602 Cohort B
Bristol Myers Squibb
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation
RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NonSmall Cell Lung CA
Solitary plasmacytoma of bone: Randomized phase III trial to evaluate treatment with adjuvant systemic treatment and zoledronic acid versus zoledronic acid after definite radiation therapy
A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)